Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer – August 2022

Pages: 14 Published: August 31, 2022 Report Code: GDHCHT347

  • Overview
  • Key Players
  • Contents
  • FAQ
  • Listen
    Powered by iSpeech

The urgent need for effective preventive vaccine and efficacious therapeutics for COVID-19 has given rise to an unprecedented pace of R&D by the biopharmaceutical industry, coupled with substantial investment by governments, non-profit agencies, and other stakeholders. There are currently more than 1,800 assets in development for COVID-19, the majority of which are very early-stage or have little data available.

The Coronavirus Disease 2019 (COVID-19) clinical and commercial analyzer report looks at the data from clinical trials for vaccines and therapeutics either currently marketed or in the pipeline. The data is assessed, and the different products are compared against each other both clinically and commercially.

Key Therapeutics in the COVID-19 Clinical and Commercial Market

Some of the key therapeutics in the COVID-19 clinical and commercial market are remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, nirmatrelvir + ritonavir, bebtelovimab (LYCoV-1404MAB), tixagevimab + cilgavimab, molnupiravir, and baricitinib.

Key Vaccines in the COVID-19 Clinical and Commercial Market

Some of the key vaccines in the COVID-19 clinical and commercial market are BNT162b2, BBIBP-CorV, mRNA-1273, Gam-COVID-Vac, Aurora-CoV, AZD1222, NVX-CoV2373, BBV152, Ad5-nCoV, and COVID-19 Vaccine (Vero Cell).

Key Companies in the COVID-19 Clinical and Commercial Market

Some of the key companies in the COVID-19 clinical and commercial market are Pfizer, BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, CureVac, Sanofi, GlaxoSmithKline, and Arcturus.

For more information on the COVID-19 clinical and commercial market, download a free report sample

COVID-19 Clinical and Commercial Market Report Overview

Key Therapeutics  remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, nirmatrelvir + ritonavir, bebtelovimab (LYCoV-1404MAB), tixagevimab + cilgavimab, molnupiravir, and baricitinib
Key Vaccines BNT162b2, BBIBP-CorV, mRNA-1273, Gam-COVID-Vac, Aurora-CoV, AZD1222, NVX-CoV2373, BBV152, Ad5-nCoV, and COVID-19 Vaccine (Vero Cell)
Key Companies Pfizer, BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, CureVac, Sanofi, GlaxoSmithKline, and Arcturus

Scope

This report provides:

  • In-depth assessment of the marketed and pipeline products for COVID-19, analyzing the clinical and commercial aspects of the products against one another.
  • A weighted view of the impact of the Omicron variant on the products.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of marketed and pipeline products and technologies, and by identifying the companies with the most robust pipeline and marketed products.
  • Understand the strengths and weaknesses of pipeline and marketed products, and how they compare against one another.
  • Develop business strategies by understanding the trends shaping and driving the COVID-19 market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global COVID-19 vaccine and therapeutic market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

Pfizer

BioNTech

Moderna

AstraZeneca

Johnson & Johnson

Novavax

CureVac

Sanofi

GlaxoSmithKline

Arcturus

Medicago

Valneva

Inovio

Sinopharm

Gamaleya Research Institute

Bharat Biotech

CanSino Biologics

Sinovac Biotech

Chongqing Zhifei

Clover Biopharmaceuticals

Medicago

Vaxart

Gilead

Fujifilm

Vir Biotechnology

Roche

Chugai

Eli Lilly

Merck

Regeneron

Celltrion

Alexion

Synairgen

Octapharma

CytoDyn

Humanigen

Abcellera

NeuroRx

Relief Therapeutics

RedHill

Novartis

Molecular Partners

EUSA Pharma

Table of Contents

Table of Contents (Excel Sheet)

1.1 Catalyst

1.2 Scope & Methodology

1.3 Clinical and Commercial Analyzer: Therapeutics

1.4 Competitive Assessment: Therapeutics

1.5 Product Dashboard: Therapeutics

1.6 Clinical Data: Therapeutics

1.7 Clinical and Commercial Analyzer: Vaccines

1.8 Competitive Assessment: Vaccines

1.9 Product Dashboard: Vaccines

1.10 Clinical Data: Vaccines

1.11 About GlobalData

Frequently Asked Questions

Some of the key therapeutics in the COVID-19 clinical and commercial market are remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, nirmatrelvir + ritonavir, bebtelovimab (LYCoV-1404MAB), tixagevimab + cilgavimab, molnupiravir, and baricitinib. 

Some of the key vaccines in the COVID-19 clinical and commercial market are BNT162b2, BBIBP-CorV, mRNA-1273, Gam-COVID-Vac, Aurora-CoV, AZD1222, NVX-CoV2373, BBV152, Ad5-nCoV, and COVID-19 Vaccine (Vero Cell).

Some of the key companies in the COVID-19 clinical and commercial market are Pfizer, BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, CureVac, Sanofi, GlaxoSmithKline, and Arcturus.

$2495

Can be used by individual purchaser only

$7485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.